Goa, May 12 -- Elsa Angel Rose

Initially, the drug was not accessible to everyone, only for the 'elite', as the drug cost a fortune. But in March 2026, with the expiry of the patent for semaglutide, the key molecule used to produce weight-loss drugs like Ozempic and Wegovy, several Indian pharmaceutical companies moved to launch lower-cost generic versions, opening up new competition in a fast-growing market for obesity treatment and offering more affordable versions of the Ozempic and Wegovy drugs. The patent for Mounjaro, wherein Tirzepatide is the major ingredient, has not expired yet. According to its company, Novo Nordisk India, low doses of Ozempic and Wegovy are now being sold in India for as little as $20. Generic alternatives ar...